- Home
- QCLS vs BIVI Comparison
QCLS vs BIVI Comparison
Compare QCLS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCLS
- BIVI
- Stock Information
- Founded
- QCLS 2014
- BIVI 2013
- Country
- QCLS United States
- BIVI United States
- Employees
- QCLS N/A
- BIVI N/A
- Industry
- QCLS Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- QCLS Health Care
- BIVI Health Care
- Exchange
- QCLS Nasdaq
- BIVI Nasdaq
- Market Cap
- QCLS 12.5M
- BIVI 14.2M
- IPO Year
- QCLS N/A
- BIVI N/A
- Fundamental
- Price
- QCLS $3.80
- BIVI $1.80
- Analyst Decision
- QCLS
- BIVI
- Analyst Count
- QCLS 0
- BIVI 0
- Target Price
- QCLS N/A
- BIVI N/A
- AVG Volume (30 Days)
- QCLS 1.3M
- BIVI 152.4K
- Earning Date
- QCLS 11-13-2025
- BIVI 11-11-2025
- Dividend Yield
- QCLS N/A
- BIVI N/A
- EPS Growth
- QCLS N/A
- BIVI N/A
- EPS
- QCLS N/A
- BIVI N/A
- Revenue
- QCLS N/A
- BIVI N/A
- Revenue This Year
- QCLS N/A
- BIVI N/A
- Revenue Next Year
- QCLS N/A
- BIVI N/A
- P/E Ratio
- QCLS N/A
- BIVI N/A
- Revenue Growth
- QCLS N/A
- BIVI N/A
- 52 Week Low
- QCLS $3.24
- BIVI $1.42
- 52 Week High
- QCLS $174.27
- BIVI $38.50
- Technical
- Relative Strength Index (RSI)
- QCLS N/A
- BIVI 41.59
- Support Level
- QCLS N/A
- BIVI $1.83
- Resistance Level
- QCLS N/A
- BIVI $1.94
- Average True Range (ATR)
- QCLS 0.00
- BIVI 0.11
- MACD
- QCLS 0.00
- BIVI 0.00
- Stochastic Oscillator
- QCLS 0.00
- BIVI 3.53
About QCLS Q/C Technologies Inc. Common Stock
Q/C Technologies Inc is engaged in building blockchain infrastructure that is faster and more energy-efficient. The company uses laser-based processors inspired by quantum technology that can solve complex problems at the speed of light. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.